There are 20 biosimilar adalimumab drugs in development – including one from Amgen that has already been approved but not yet launched. Biotechs and big pharma companies alike are lining up their candidates in preparation for when AbbVie's world-leading inflammation and immunology product Humira loses patent protection.
Biosimilar versions of the world's bestselling drug, AbbVie Inc.'s Humira (adalimumab), are lurking all over the globe in shadows cast by the originator product, ready to hit the market as soon as patent protection is lost for the drug, which is the major engine driving AbbVie's revenues and profits.
Humira, a tumor necrosis factor (TNF) inhibitor approved for several inflammatory indications, is still the main source of growth for...
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
